Management of Relapsed/Refractory Follicular Lymphoma

Sameh Gaballa, MD, discusses patients who relapse after frontline treatment as well as prognostic and predictive factors for relapse.

An expert in follicular lymphoma highlights factors to consider when choosing therapy for first relapse and how this impacts later line treatment, as well as molecular testing and MRD.

Sameh Gaballa, MD, considers therapeutic options in the third-line setting and beyond for patients who relapse.

Sameh Gaballa, MD, discusses molecular testing in the third-line setting and beyond, as well as the mechanism of action of tazemetostat in the treatment of relapsed/refractory follicular lymphoma.

A key opinion leader reviews the role of PI3K kinase inhibitors in the third-line or later settings for the treatment of follicular lymphoma.

Sameh Gaballa, MD, focuses on unmet needs and the future of the treatment landscape for follicular lymphoma.

This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.